5-benzyloxy-3H-benzooxazole-2-thione | 213685-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 5-benzyloxy-3H-benzooxazole-2-thione
• 英文别名: 2-mercapto-5-benzyloxybenzoxazole；5-(Phenylmethoxy)-2(3H)-benzoxazolethione；5-phenylmethoxy-3H-1,3-benzoxazole-2-thione
• CAS: 213685-60-0
• 化学式: C₁₄H₁₁NO₂S
• 分子量: 257.313
• InChiKey: DUVRWOLRJRFGNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-benzyloxy-3H-benzooxazole-2-thione 在 sodium hydroxide 、 五氯化磷 、 一水合肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 苯 为溶剂， 反应 3.0h， 生成 3-[N-(5-Benzyloxy-benzooxazol-2-yl)-hydrazino]-propionitrile
  参考文献：
  名称：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation

  摘要：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.

  DOI：

  10.1021/jm00117a010
• 作为产物：
  描述：

  2-硝基-4-(苯基甲氧基)-苯酚 在 溶剂黄146 、 锌 作用下， 以 乙醇 为溶剂， 反应 25.0h， 生成 5-benzyloxy-3H-benzooxazole-2-thione
  参考文献：
  名称：

  设计，合成和药理的主动脉选择性酰基辅酶A：胆固醇O酰基转移酶（ACAT / SOAT）抑制剂

  摘要：

  我们描述了我们的主动脉选择性酰基辅酶A：胆固醇O-酰基转移酶（ACAT，也缩写为SOAT）抑制剂的分子设计，其结构-活性关系（SARs）以及它们的药代动力学（PK）和药理学特征。两个弱配体-N-（2,6-二异丙基苯基）乙酰胺（50％抑制浓度[IC 50 ] = 8.6μM）和2-（甲硫基）苯并[ d ]恶唑（IC 50  = 31μM）的连接包括6支亚甲基链的连接体，得到一种高度有效分子，9-（苯并[ d ]恶唑-2-基硫基） - ñ - （2,6-二异丙基）壬酰胺（3H），其表现出高效力（IC 50 = 0.004μM）朝向主动脉ACAT。这种从头到尾的设计使将活性显着提高到2150至7750倍，并基于双重诱导的拟合机制来区分同工型选择性成为可能。在1 mg / kg和3 mg / kg的剂量下，3h显着降低了主动脉弓的脂质蓄积面积，分别降至74％和69％，而没有降低高脂和高胆固醇喂养的F

  DOI：

  10.1016/j.bmc.2018.06.024

文献信息

• Anilide compounds and drugs containing the same
  申请人：Kowa Company, Ltd.

  公开号：US06362208B1

  公开（公告）日：2002-03-26

  The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents —NH—, oxygen atom or sulfur atom; Y represents —NR4—, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR5—; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

  该发明涉及一种新型苯胺类化合物和包含该化合物的药物组合物。该发明涉及一种由以下通用式表示的化合物：表示苯的一个带有取代基的二价残基，杂环并联苯可能具有或不具有取代基，吡啶可能具有或不具有取代基，环己烷或萘或Ar代表可能具有或不具有取代基的芳基；X代表—NH—、氧原子或硫原子；Y代表—NR4—、氧原子、硫原子、亚硫醚或砜；Z代表单键或—NR5—；R4代表氢原子、较低烷基、芳基或可能具有或不具有取代基的硅烷化较低烷基；R5代表氢原子、较低烷基、芳基或可能具有或不具有取代基的硅烷化较低烷基；n代表0到15之间的整数。这些创新化合物在药物组合物的形式中非常有用，特别作为酰辅酶A胆固醇酰转移酶（ACAT）抑制剂。
• NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME
  申请人：Kowa Co., Ltd.

  公开号：EP1020451A1

  公开（公告）日：2000-07-19

  The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula:    represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents -NH-, oxygen atom or sulfur atom; Y represents -NR4-, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or -NR5-; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

  本发明涉及一种新型苯胺化合物和含有该化合物的药物组合物。本发明涉及由以下通式代表的化合物： 代表带有取代基的苯、可能带有也可能不带取代基的杂环缩合苯、可能带有也可能不带取代基的吡啶、环己烷或萘的二价残基 或 Ar 代表芳基，可以有取代基，也可以没有取代基； X 代表-NH-、氧原子或硫原子； Y 代表-NR4-、氧原子、硫原子、亚砜或砜； Z 代表单键或-NR5-； R4 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可带有或不带有取代基； R5 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可以有或没有取代基；以及 n 代表 0 至 15 的整数。 本发明化合物以药物组合物的形式使用，特别是作为酰基辅酶 A 胆固醇酰基转移酶（ACAT）抑制剂。
• Novel anilide compounds and drugs containing the same
  申请人：Kowa Company, Ltd.,Japan

  公开号：US20020099074A1

  公开（公告）日：2002-07-25

  The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: 1 represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene 2 Ar represents an aryl group which may or may not have a substituent, X represents —NH—, oxygen atom or sulfur atom; Y represents —NR 4 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR 5 —; R 4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R 5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

  本发明涉及一种新型苯胺化合物和含有该化合物的药物组合物。本发明涉及一种由以下通式表示的化合物： 1 代表带有取代基的苯、可以带有或不带有取代基的杂环缩合苯、可以带有或不带有取代基的吡啶、环己烷或萘的二价残基 2 Ar 代表芳基，可以有取代基，也可以没有取代基、 X 代表-NH-、氧原子或硫原子； Y 代表-NR 4 -、氧原子、硫原子、亚砜或砜； Z 代表单键或-NR 5 -; R 4 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可带有或不带有取代基； R 5 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可带有或不带有取代基；以及 n 代表 0 至 15 的整数。 本发明化合物以药物组合物的形式使用，特别是作为酰基辅酶 A 胆固醇酰基转移酶（ACAT）抑制剂。
• Basic ethers of 2-anilinobenzothiazoles and 2-anilinobenzoxazoles as potential antidepressants
  作者：C. J. Sharpe、P. J. Palmer、D. E. Evans、G. R. Brown、Gillian King、R. S. Shadbolt、R. B. Trigg、R. J. Ward、A. Ashford、Janet W. Ross

  DOI：10.1021/jm00275a022

  日期：1972.5
• Nakao, Kazuya; Asao, Masaaki; Shirai, Hiroki, Medicinal Chemistry Research, 1999, vol. 9, # 7-8, p. 631 - 642
  作者：Nakao, Kazuya、Asao, Masaaki、Shirai, Hiroki、Saito, Kiyoshi、Moriya, Tamon、Iwata, Hiroshi、Matsumoto, Mamoru、Matsuoka, Yuzo、Shimizu, Ryo

  DOI：——

  日期：——